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Celiac disease (CD), or gluten-sensitive enteropathy, is a common multifactorial disorder resulting from intolerance
to cereal prolamins. The only established genetic susceptibility factor is HLA-DQ, which appears to explain only
part of the overall genetic risk. We performed a genomewide scan of CD in 60 Finnish families. In addition to
strong evidence for linkage to the HLA region at 6p21.3 ( ), suggestive evidence for linkage was found forZ 1 5max
six other chromosomal regions—1p36, 4p15, 5q31, 7q21, 9p21-23, and 16q12. We further analyzed the three
most convincing regions—4p15, 5q31, and 7q21—by evaluation of dense marker arrays across each region and
by analysis of an additional 38 families. Although multipoint analysis with dense markers provided supportive
evidence (multipoint LOD scores 3.25 at 4p15, 1.49 at 5q31, and 1.04 at 7q21) for the initial findings, the additional
38 families did not strengthen evidence for linkage. The role that HLA-DQ plays was studied in more detail by
analysis of DQB1 alleles in all 98 families. All but one patient carried one or two HLA-DQ risk alleles, and 65%
of HLA-DQ2 carriers were affected. Our study indicates that the HLA region harbors a predominant CD-suscep-
tibility locus in these Finnish families.
Introduction
Celiac disease (CD [MIM 212750]) is a multifactorial
disorder of the small intestine and results from intol-
erance to prolamins from wheat, barley, and rye. CD
can have different manifestations, ranging from overt
clinical cases to milder silent cases (Ma¨ki and Collin
1997). The prevalence of CD has, until recently, been
estimated to be 11/1,000. However, recent data from
various populations in Europe and the United States
(Not et al. 1998) suggest a much higher prevalence, of
0.4%–1%. Development of CD is known to be influ-
enced by both environmental (gluten) and genetic (HLA)
factors. Disease prevalence among first-degree relatives
of affected individuals has been reported to be ∼10%
(Ellis 1981; Ma¨ki et al. 1991), and the concordance rate
among MZ twins has been reported to be 170% (Po-
lanco et al. 1981; Hervonen et al. 2000; Greco et al., in
press).
Although the pathogenic mechanism of CD is not
known, it has been clear for some time that the immune
system is involved. CD susceptibility is strongly asso-
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ciated with the risk alleles DQA1*05 and DQB1*02,
which encode the heterodimeric HLA-DQ2 molecule (in
cis in the DR3 haplotype and in trans in the DR5/7
heterozygotes). To date, 190% of patients with CD in
most populations that were tested carry the DQ2 het-
erodimer (Spurkland et al. 1990). In addition, the DQ8
molecule, which is encoded by the DQA1*03 and
DQB1*0302 alleles, has been shown to associate with
CD in cases in which DQ2 is not present (Spurkland et
al. 1992; Polvi et al. 1998). In summary, a key role that
DQ2 and DQ8 play in disease pathogenesis has been
described (Sollid 2000) that establishes the HLA-DQA1
and HLA-DQB1 loci as the principal CD-associated ge-
netic determinants in the HLA region.
Despite its strong association with CD, HLA-DQ
likely explains only part of the genetic susceptibility.
Evidence for the existence of other genetic factors comes
mainly from three sources. First, although almost all
patients carry the DQ risk molecules, 22% of indi-
viduals in the general Finnish population also carry the
DQ2 risk molecules (Partanen and Westman 1997) and
still remain unaffected despite cereal intake; therefore,
only a small portion (∼5%) of individuals positive for
DQ2 subsequently develop CD, suggesting that, al-
though certain DQ alleles are necessary for the devel-
opment of disease, other genetic or environmental risk
factors must also exist. Second, although, for CD, the
concordance rate among MZ twins is 170%, the con-
cordance rate among DQ-risk-allele–identical siblings is
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only ∼30% (Mearin et al. 1983; Petronzelli et al. 1997);
the difference between these two rates indicates that
other genetic factors may play a role in the development
of CD. Third, several family-based studies have been
conducted to estimate recurrence risk, along with the
population risk ( ), for CD in siblings (with or withoutl s
identical HLA alleles) (Rotter and Landaw 1984; Risch
1987; Petronzelli et al. 1997; Bevan et al. 1999); from
such studies, the HLA-associated risk factor was esti-
mated to account for 29%–40% of overall CD famil-
iarity. It should be pointed out, however, that because
DQ risk alleles are so common in the general popu-
lation, estimates based solely on identical-by-descent
(IBD) calculations are expected to bias the results.
In an attempt to identify non-HLA genetic factors
related to CD, three independent genomewide-mapping
studies on CD have been conducted. The first, from
western Ireland, analyzed 15 families with 40 affected
siblings (Zhong et al. 1996). In addition to the HLA
region that demonstrated strong linkage to CD, six
other regions—a secondary region on 6p, as well as
7q31, 11p11, 15q26, 19q, and 22cen—were reported
to yield suggestive evidence for linkage. Subsequently,
the non-HLA regions that were implicated from the
Irish study were reexamined by Houlston et al. (1997)
and Brett et al. (1998), by use of independent sample
sets. Although the former study showed moderate evi-
dence for linkage in the 15q26 region, the latter study
did not find any evidence for linkage from these regions.
A second genomewide-mapping study analyzed 110
Italian sib pairs (Greco et al. 1998) and provided sug-
gestive evidence for linkage to chromosome 5q. From
the same study, analysis of a subset of 39 sib pairs, in
which both siblings manifested a symptomatic form of
CD, provided suggestive evidence for linkage to chro-
mosome 11q. Interestingly, this finding was not repli-
cated in the remaining 71 sib pairs in which one sibling
displayed symptomatic CD and the other sibling was
diagnosed with a silent form of CD. Recently, Greco et
al. (2001) have presented further evidence, from an in-
dependent sample set, in support of linkage to chro-
mosome 5q. Recent candidate-gene studies performed
in Finnish families likewise are consistent with the re-
ported linkage at chromosomes 5q and 11q (Holopai-
nen et al. 2001). A third genome scan with 16 multiplex
families from the United Kingdom reported putative
linked loci at 10q and 16q and supporting evidence for
linkage to 6q, 11p, and 19q, three suggested regions in
the first genome scan from western Ireland (King et al.
2000). By use of a candidate-gene approach, evidence
is accumulating that the CTLA4/CD28 gene region on
chromosome 2q33 may, in the northern European pop-
ulations, confer susceptibility to CD (Holopainen et al.
1999; Torinsson Naluai et al. 2000). For all non-HLA
loci thus far reported, evidence for genetic linkage or
association is moderate and inconclusive.
In the present study, a genomewide-mapping ap-
proach was used to search for non-HLA genetic factors
for CD in a collection of families from Finland, a pop-
ulation that has been characterized by a somewhat less
diverse gene pool and by the identification of founder
effects for a number of single-gene diseases (de la Cha-
pelle 1993; Peltonen et al. 1999). Perhaps more impor-
tantly, the cultural and environmental variability is, in
comparison to that of many other populations, low in
the Finnish population; the population is unusually co-
operative for genetic studies; and there are reliable and
extensive computerized medical and population records
available for research purposes. The Finnish population
has proved to be extremely valuable for the mapping
of rare single-gene defects, although its advantages for
the study of more-common diseases remain unproved.
In the present study, genomewide mapping was initially
performed with 60 families, each with multiple affected
individuals. The three most interesting regions of the
genome (other than HLA) were further investigated by
the genotyping of additional markers and of an addi-
tional 38 families. The role that HLA-DQ plays in the
familial aggregation of disease was further examined in
the family sample by genotyping DQB1, a well-estab-
lished and reliable assay for the CD-associated DQ2
molecule.
Families, Material, and Methods
Families
Families were initially recruited through the Finnish
Coeliac Society, by advertising in the patients’ newsletter.
Of the families who volunteered, those with at least one
affected sib pair were accepted for further evaluation.
The earlier diagnoses were then reevaluated by scrutin-
ization of the medical records. Healthy family members
were screened for antiendomysium antibody activity,
and ∼10% were found to have an asymptomatic form
of the disease. Diagnosis based on small-bowel biopsy
while on normal gluten-containing diet was obtained for
all but 17 of 256 patients, for whom no definitive evi-
dence based on biopsy was available. Thirty-five patients
had dermatitis herpetiformis, and 20 were asymptomatic
patients who were found by screening of the family
members. Median age at diagnosis was 37 years. All
families were of apparent Finnish origin, and there was
no evidence for any particular clustering in their current
places of residence. Sixty families with multiple affected
siblings were selected for genomewide mapping. Among
these families, 39 had two affected siblings, 16 had three
affected siblings, and 5 had four affected siblings. Only
affected siblings and parents (when available) were ge-
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Table 1
Six Markers Reaching LOD Scores 11 in Genomewide Analysis of
60 Families with CD
MARKER
LOD SCORE ASSUMING
Dominant
Inheritance
Recessive
Inheritance
High
Penetrance
Low
Penetrance
High
Penetrance
Low
Penetrance
D1S3669 1.09 0 .16 .09
D4S2639 1.25 2.11 .97 1.19
D5S816 1.72 .97 1.73 .43
D7S821 1.02 .66 .35 .40
D9S741 .65 .50 1.08 1.11
D16S3253 .21 .43 .93 1.40
NOTE.—Two-point analyses with four models—under the assump-
tion of a risk allele with either high or low penetrances and either
dominant or recessive inheritance—were performed.
notyped, except in nine families for whom one or two
unaffected siblings were genotyped to increase the
marker informativeness. Both parents were available in
19 families; only one parent was available in 20 families;
and neither parent was available in 21 families. Alto-
gether, 9 parents were affected, thereby resulting, to-
gether with 4 other relatives affected, in 159 patients
with CD studied genomewide.
For the follow-up study of the three most interesting
regions, 38 additional families with multiple affected
siblings—28 families with two affected siblings, 8 fam-
ilies with three affected siblings, and 2 families with four
affected siblings—were studied. Both parents were avail-
able in 23 families, one parent was available in 4 fam-
ilies, and neither parent was available in 11 families.
Altogether, 9 parents were affected, thereby resulting in
97 patients studied in these additional families.
For HLA-DQB1 alleles, all family members were geno-
typed in 98 families. One to seven healthy siblings were
available in 54 families, thereby resulting in a total of 260
affected and 237 healthy family members genotyped.
Genotyping
A genomewide screen was performed with 352 mi-
crosatellite markers with an average marker space of 9.6
cM. All markers were screened by a semiautomatic fluo-
rescence-labeled genotyping system (Reed et al. 1994;
Ghosh et al. 1997). In brief, multiplex PCR was per-
formed in 384-well PCR plates (Marsh) and PTC 225
thermocyclers (MJ Research) with a total volume of 10
ml containing 50 ng of genomic DNA, 0.15–0.2 mM
MgCl2, 0.2 mM dNTPs, and 0.5 units of Taq Platenum
polymerase (Gibco Life Tech). On average, each multi-
plex PCR contains four markers with various amounts
(1–50 pmol) of primer, to achieve roughly even ampli-
fication of each marker. PCR products from two to three
multiplex PCR reactions were pooled and then geno-
typed by 377 DNA sequencers and the GENESCAN 2.0/
GENOTYPER 1.1.1 software (PE Applied Biosystems).
Before being imported into the genotyping database
LABMAN (Adams 1994) for allele binning and Men-
delization checking, the computer-generated genotypes
were checked by two independent researchers who are
blind to disease phenotypes.
Genotyping data were checked for Mendelian incon-
sistency, by the PedCheck program (O’Connell and
Weeks 1998). Any marker violating the rules of Men-
delian transmission was double checked by the geno-
typing laboratory. Ambiguous marker genotypes were
deleted to reduce further problems occurring during sta-
tistical analysis. The biological relationships were also
examined by the RelCheck computer program (Broman
and Weber 1998). The program uses the genotypic in-
formation from autosomal markers in the genome scan
and calculates the likelihoods to infer the relationship
of a putative sib pair. Five relationships—MZ twins,
parental/offspring, full siblings, half siblings, and unre-
lated individuals—were considered.
The HLA-DQB1 alleles were genotyped from all avail-
able family members by use of a DQ SSP “Low Reso-
lution” kit (Dynal AS). Major classes of the HLA-DQB1
alleles—including the known risk alleles DQB1*02
(DQ2) and DQB1*0302 (DQ8)—could be determined.
On the basis of our unpublished results, ∼90% of
DQB1*02 positive individuals in Finnish families with
CD have the DQA1*05 DQB1*02 haplotype.
Linkage Analysis
Allele frequencies from all individuals genotyped were
estimated by the GCONVERT program. Together with
the likelihood-based analysis that was used, this con-
servative estimation of frequencies diminishes the risk
of type I error due to lack of parental genotypes in part
of the families (Go¨ring and Terwilliger 2000a). Analyses
were performed by a pseudomarker approach (Go¨ring
and Terwilliger 2000a, 2000b), which approximates a
“model-free” affected-relative-pair analysis, but main-
tains an important property of LOD-score analysis—
that is, that pedigree correlations between all relatives
are considered jointly, and the pedigree is not broken
into a set of all possible relative pairs. Since the actual
mode of inheritance for CD is unknown, both dominant
and recessive models were applied to our analyses. Two
dominant models (one with high penetrance and the
other with very low penetrance; neither allowing for
phenocopies; and each assuming the disease allele to be
infinitesimally rare, according to the pseudomarker
strategy [Go¨ring and Terwilliger 2000b]) were per-
formed. Similarly, the same parameters and assumptions
were used in the two recessive models. Because of com-
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Table 2
Two-Point and Multipoint LOD Scores of the Follow-Up Analysis of Three Regions
MARKERa
MAP
POSITIONb
(cM)
INITIAL 60 FAMILIES ALL 98 FAMILIESc
Two-Point
LOD Score
Multipoint
LOD Scored
Two-Point
LOD Score
Multipoint
LOD Scored
D4s2960 29.1 0 0
D4s2639 29.8 2.11 1.05 1.33 .63
D4s2633 33.4 2.14 3.25 1.78 2.40
D4s3017 35.6 .68 1.38 .19 .69
D4s2397 42.7 .78 1.61 .37 .34
D5s642 134.7 .08 .09
D5s1995 138.0 .33 .68 .25 .42
D5s2115 138.6 .43 .55 .36 .29
D5s396 139.3 .34 .46 .15 .10
D5s458 139.3 .33 .55 .17 .27
D5s816 139.3 1.72 1.49 1.81 1.00
D5s500 140.7 1.56 1.50 1.62 1.52
D5s1480 147.5 .46 1.20 .21 1.11
D7s479 109.1 .0 .03
D7s821 109.1 1.01 .39 .84 1.02
D7s2480 111.3 .96 1.04 .73 1.30
D7s1799 113.9 .51 .89 .63 .83
a Underlined markers are those used in the initial genomewide analysis.
b Map distances are based on the genetic map from Marshfield Genetic Laboratory (Center for Medical
Genetics, Marshfield Medical Research Foundation).
c Ninety-nine families were analyzed for the markers from 5q region.
d Three-point analysis was performed using the current marker and that above it.
putational restrictions, multipoint analyses were con-
ducted by joining the meiotic information from two
neighboring markers at one time (i.e., by three-point
analysis). Two-point and multipoint pseudomarker anal-
yses were performed by the FASTLINK program (Cot-
tingham et al. 1993). In multipoint analyses, we used
only the genetic models that yielded the highest LOD
scores in two-point analysis.
Results
Two-Point Genomewide Analysis of 60 Families
The only highly significant finding over all models
tested was a LOD score 15 for marker D6s1281, which
maps adjacent to the HLA gene region. Six other mark-
ers—D1s3669, D4s2639, D5s816, D7s821, D9s741,
and D16s3253—yielded LOD scores 11 (table 1). The
maximum LOD scores over the four tested models were
1.09 for D1s3669 and 1.02 for D7s821, under the as-
sumption of a high-penetrance gene with dominant in-
heritance, and 2.11 for D4s2639, under the assumption
of a dominant, low-penetrance gene. The best LOD
scores under the assumption of a recessive inheritance
were 1.73 for D5s816, for a high-penetrance gene, and
1.11 for D9s741 and 1.40 for D16s3253, assuming a
low-penetrance gene.
Follow-Up Analysis with Additional Markers and 38
Families
Three of the linked regions—chromosomes 4p15,
5q31, and 7q21—were selected for follow-up analysis
based on statistical evidence for linkage to CD and/or
based on independent evidence for linkage in earlier ge-
nome scans. In the follow-up study, additional adjacent
markers spanning the implicated genetic regions were
genotyped in the original 60 families and in an additional
38 Finnish families. The follow-up linkage analyses were
performed based on the same model that yielded the best
LOD scores in the genome scan. The results of the fol-
low-up analyses are summarized in table 2. Two-point
analysis of the original 60 families with the new markers
provided consistent evidence for linkage for some of the
adjacent markers. The multipoint analysis with dense
markers gave stronger evidence for linkage in the 4p
region, with a LOD score of 3.25, and consistent evi-
dence for linkage in the chromosomes 5q and 7q, with
LOD scores of 1.49 and 1.04, respectively. Linkage anal-
ysis of the 38 new families alone did not provide sup-
porting evidence for any of the three regions (data not
shown), which is not surprising considering the smaller
sample. Linkage analysis of the combined 98 families
did not markedly strengthen evidence for linkage in any
of three regions.
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Table 3
CD Prevalence in Relation to HLA Risk Status
among 497 Family Members in 98 Families
DQ Status
No. Affected/No.
Unaffected (CD
Prevalence)
DQ2:
Heterozygous 175/117 (60%)
Homozygous 77/20 (79%)
Overall 252/137 (65%)
DQ2/DQ8 1/75 (1%)
DQ2/DQ8 7/25 (22%)
Overall 260/237 (52%)
Known Risk Alleles at HLA-DQB1, in 98 Families
HLA-DQB1 alleles were determined, in all available
family members in the 98 families. The DQB1*02 allele
forms part of the DQ2 heterodimer, a well-known risk
factor for CD. Altogether, 497 individuals—of whom
260 were affected and 237 were unaffected—were geno-
typed. The distribution of the DQ risk alleles in our
family sample was as expected for CD. Only one affected
individual did not carry either a DQ2 (DQB1*02) or a
DQ8 (DQB1*0302) risk allele. DQ2 was found in all
but three of the families. Disease prevalence in relation
to the DQ risk status is shown in table 3. Of the 389
DQ2-positive family members, 252 were affected,
thereby resulting in a disease prevalence of 65% for all
DQ2 carriers—without any correction for ascertain-
ment. Difference in prevalence was observed between
individuals carrying one copy of DQ2 and individuals
carrying two copies of DQ2 (with prevalences of 60%
and 79%, respectively). In contrast, prevalence did not
differ between DQ2 heterozygous persons carrying ei-
ther DQ8 or nonrisk DQ alleles (data not shown). Al-
though it is interesting, the significance of these obser-
vations is not clear, because our family ascertainment
plan, designed to maximize the power for detection of
linkage, obviously biases estimation of prevalence.
Although linkage between chromosome 6p markers
proximal to HLA and CD was definitive (LOD score 15)
in the 60 families, the strength of linkage was also tested
directly by assaying DQB1 alleles in the combined 98
families. Pseudomarker analysis was performed using the
most obvious dominant inheritance model on the basis
of DQ2 characteristics in the family sample—penetrances
of 60% and 79%, for individuals who are heterozygous
or homozygous carriers, respectively, for risk alleles; phe-
nocopy rate of 0%; and a risk allele frequency of 13%
in the population (Partanen and Westman 1997). As ex-
pected, highly significant evidence for linkage was ob-
served (maximum LOD score 19.6).
Discussion
Genomewide linkage analysis was performed with 60
Finnish families with CD, and subsequent analysis of the
three most interesting findings was performed, together
with analysis of 38 additional families, with a denser
marker array across the implicated regions. Finland has
proved to be a particularly interesting study population
for genetic analyses. Importantly, in the Finnish popu-
lation, cultural and environmental heterogeneity is lower
than it is in many other populations, and medical records
are reliable and comparable. The Finnish population has
a relatively homogeneous gene pool, and many studies
have identified strong founder effects. Together, these
characteristics have facilitated successful mapping of sin-
gle-gene defects (Peltonen et al. 1999). The level of link-
age disequilibrium in the general population may not,
however, be significantly different from that in other
populations (Laan and Paabo 1997; Eaves et al. 2000),
and, in general, it is not clear whether the Finnish pop-
ulation offers a significant advantage in the search of
complex-disease alleles. It is certainly true that, in
smaller, more isolated populations, there would be a
reduction of environmental and genetic (both locus and
allelic) heterogeneity; however, what remains to be seen
is whether this reduction in heterogeneity will be suffi-
cient, in populations as large as that of Finland, to make
feasible the identification of risk factors for complex
traits. In Finland, the HLA genetic component of CD is
rather simple; ∼90% of patients carry the HLA-DQ2
risk molecule, and the remaining ∼10% usually carry
the HLA-DQ8 risk molecule. Also, most individuals in
Finland constantly ingest cereals—that is, they encoun-
ter the major environmental trigger for the disease.
In view of this background of population homoge-
neity and founder effect, it is interesting that our study
produced only moderate evidence for a non-HLA ge-
netic component to CD. The only definitive genetic lo-
cus identified was HLA, which appears to be the major
susceptibility locus, which carries the known CD risk
genes DQA1 and DQB1. Six additional regions showed
suggestive evidence for linkage; the most impressive re-
gion around locus D4s2623 produced a multipoint
LOD score of 2.4 in the 98 families. This may result
from a higher level of locus heterogeneity for non-HLA
risk factors between, as well as within, the popula-
tions—even in the relatively homogeneous Finnish pop-
ulation. The role that non-HLA loci play in disease sus-
ceptibility may also be much more complex than that
played by HLA, perhaps featuring epistatic interactions
between multiple loci and possibly including diverse en-
vironmental factors.
Two-point LOD scores of 1.02–2.11 were found for
non-HLA regions on chromosomes 1p36, 4p15, 5q31,
Table 4
Summary of Evidence for Linkage, for CD
CHROMOSOME
EVIDENCE FROM STUDY (SAMPLE)
Zhong et al. (1996)
(40 Sib Pairs)
Greco et al. (1998)
(37 or 110 Sib Pairs)
Greco et al. (2001)
(182 Sib Pairsa)
King et al. (2000)
(16 Families)
Present Study
(60 or 98 Families)
Locus
Position
(cM) MMLSb Locus
Position
(cM) MMLSb Locus
Position
(cM) MMLSb Locus
Position
(cM) MMLODc Locus
Position
(cM) MLSd MMLSe
1p D1s3669 37 1.90
4p D4s2633 33 2.11 3.25 (2.40)
5q D5s211–D5s498 183–185 .92 D5s2111–D5s2006 188–198 2.0 D5s640 153 2.92 D5s816 139 1.73 1.49 (1.00)
6p D6s259–D6s469 28–30 4.66
6q D6s460 90 1.2
7q D7s480–D7s1809 126–128 2.99 D7s2480 111 1.02 1.04 (1.30)
9p D9s741 43 1.08
10q D10s597 129 1.9
11p D11s871–D11s1385 58 3.92 D11s935 46 1.5
11q D11s4142–D11s934 111–126 1.8
15q D15s207–D15s107 102–109 2.12
16q D16s3091 111 1.9 D16s3253 72 1.40
19q D19s418 92 1.84 D19s210 100 .9
22(cen) D22s420 4 2.69
a Overlaps with the sample in an earlier study by Greco et al. (1998).
b MMLS p multipoint maximum LOD score; determined by MAPMAKER/SIBS.
c MMLOD p multipoint maximum LOD score; determined by VITESSE/MFLINK programs.
d MLS p two-point LOD scores; determined by pseudomarker analysis, by FASTLINK, of 60 families.
e Determined by pseudomarker analysis, by FASTLINK, of 60 or 98 (in parentheses) families.
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7q21, 9p21-23, and 16q12. The highest two-point LOD
score, 2.11, was generated on chromosome 4p. Regions
on chromosomes 5q and 7q were close to previously
implicated CD regions in independent genome scans de-
scribed elsewhere (Zhong et al. 1996; Greco et al. 1998).
These three regions were reanalyzed with dense marker
coverage, in the original 60 families and an additional
38 families. Although multipoint analysis with dense
markers yielded stronger evidence for linkage on chro-
mosome 4p and consistent evidence for linkage on chro-
mosomes 5q and 7q, analysis of the combined 98 fam-
ilies did not bolster evidence for linkage in any of the
three regions. Such a finding may reflect the underlining
genetic complexity (i.e., genes of small effect or complex
gene-gene or gene-environmental interaction, together
with nonallelic heterogeneity), or they may indicate
false-positive findings. Distinction between these inter-
pretations is the challenge posed to those who undertake
complex genetic studies.
Table 4 shows the findings from this study compared
with those of other previously reported linkage studies.
Evidence from this study, for linkage to 5q31, maps 14
cM centromeric to the location in the Italian population
described elsewhere (Greco et al. 2001). Multiple
studies—including the Irish study (Zhong et al. 1996),
our candidate-gene study with Finnish families (Holo-
painen et al. 2001), and the original genome screen
reported by Greco et al. (1998)—have found hints of
linkage to the 5q telomere, ∼50 cM from 5q31. The 5q
region is of particular relevance to immune-mediated
diseases, since it harbors a cytokine-gene cluster that is
involved in the T-helper-cell subset 2 type of immune
response. The present study provided moderate evidence
for linkage at chromosome 7q, which is ∼17 cM cen-
tromeric to the locus implicated in the study by Zhong
et al. (1996). It is also notable that the pathogenic de-
letions described for Williams syndrome, a rare disease
that has been reported in association with CD (Pankau
et al. 1993; Pittschieler et al. 1993; Chiaravalloti et al.
1995; Papadatou et al. 1996), span the elastin gene at
7q11.23. However, no association to the elastin-gene
marker was found in a recent study (Grillo et al. 2000).
It is notable that, in the present study, no evidence
for linkage to candidate regions 2q33 (CTLA4/CD28
gene region) and 11q23, which were implicated in can-
didate-gene studies of 100 Finnish families (60 of whom
overlap with those in the present study), was detected.
Previous studies showed a nonparametric-linkage score
of 2.5 for locus D2s116 and a maximum-likelihood
score of 1.37 for locus D11s4142 (Holopainen et al.
1999, 2001). By comparison, denser marker sets were
used in the candidate-gene studies, relative to the whole-
genome scan. Several comparative studies provide ex-
amples of putative linkages that are undetected by ge-
nome scans at marker-interval spacing of10 cM (Aita
et al. 1999; Liu et al. 2001a, 2001b), although it is
remains unclear whether the putative linkage findings
from dense-marker analysis in the candidate-gene stud-
ies, or from our genome scan, are significant.
Linkage to HLA-DQ was extremely strong in this
sample of Finnish families with CD. All but one patient
carried the known risk factor DQ2 or DQ8. The prev-
alence of CD was 65% among all DQ2-positive family
members, 60% for individuals carrying one copy of
DQ2, and 79% for individuals carrying two copies of
DQ2. The relevance of DQ2 dose effect in CD could
not be evaluated in our sample, however, because of
strong ascertainment bias, nonindependence of family
members, and high frequency of DQ risk alleles. Meth-
ods for estimating the role that risk alleles play in disease
familiarity are not, in general, applicable to common
alleles but, specifically, are not applicable in the presence
of strong ascertainment bias, as was the case in this
study. In our sample, all but one patient carried either
the DQ2 or DQ8 risk molecule and thus rendered es-
timation of IBD sharing meaningless, since many indi-
viduals were identical-by-state for the “disease” allele
without being IBD. Estimates based solely on IBD thus
will systematically underestimate the effect of this locus.
In addition to the need to continue the search for
non-HLA genetic components to CD, it will be impor-
tant, in future studies, to explore the relative contri-
bution of HLA-related risk alleles to CD susceptibility
in Finnish families. As the HLA gene region harbors a
large number of genes involved in the immune response,
HLA-linked non-DQ genes may also contribute to CD
susceptibility. If not all DQ2 haplotypes confer equal
risk to CD, then the prevalence of the putative high-
risk DQ2 haplotypes would be higher in families with
patients with CD. Indeed, recently, Lie et al. (1999), as
well as our group (Karell et al., in press), reported ev-
idence for differences in susceptibility between DQ2-
positive haplotypes. Despite weak evidence for HLA-
unlinked genes, the present genome scan provides a
starting point for a further search for CD-susceptibility
alleles in the Finnish population.
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